DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021" report to their offering.
The global hypertrophic cardiomyopathy therapeutics market to grow at a CAGR of 1.80% during the period 2017-2021.
The report, Global Hypertrophic Cardiomyopathy Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
One trend in market is development of TBI. HCM is a complex genetic disorder, which requires an integration of various heterogeneous features originating from genotypic, phenotypic, and environmental sources. Modern approaches that can integrate and analyze these heterogeneous features are being developed in order to enhance the clinical guidelines for treatment and prevention of HCM and are named as TBI.
TBI is a computational approach, which focuses on the integration and analysis of bioinformatics, biostatics, statistical genetics, and clinical informatics. It acts as a data-storage source, which not only performs data integration but also improves data representation. This will be done by using tools such as ontology and controlled vocabulary, as they provide a standard way for representation of data. These vocabulary sources are references that are accepted by specific user community like Gene Ontology and the Systematized Nomenclature of Medicine-Clinical Terms (SNOMED-CT).
Other Prominent Vendors
- Gilead Sciences
Teva Pharmaceutical Industries
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Disease overview
PART 06: Key clinical trials
PART 07: Market dynamics
PART 08: Market landscape
PART 09: Market segmentation by drug-class
PART 10: Geographical segmentation
PART 11: Decision framework
PART 12: Drivers and challenges
PART 13: Market trends
PART 14: Vendor landscape
PART 15: Key vendor analysis
PART 16: Appendix
For more information about this report visit http://www.researchandmarkets.com/research/vtws8x/global